World's first dengue vaccine now approved in 11 countries

Image
IANS Paris
Last Updated : Oct 04 2016 | 4:22 PM IST

Sanofi-Pasteur -- a unit of French pharmaceutical company Sanofi -- that manufactures the only approved vaccine for dengue said on Tuesday that the vaccines has received approval in 14 countries.

Recent approvals for Dengvaxia granted by health authorities are those from Indonesia, Thailand and Singapore. Mexico, the Philippines, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Indonesia, Thailand and Singapore have already granted it the approval.

"We're pleased to see the growing medical and public health recognition for the vaccine," Su Peing Ng, head of Global Medical Affairs for Sanofi Pasteur, said in a statement.

"With this new tool in hand, public health communities in dengue-endemic countries now have additional means to achieve the WHO objectives for 50 per cent reduction in mortality and 25 per cent reduction in morbidity due to dengue by 2020," Su Peing Ng said.

Notably, the Latin American Society for Pediatric Infectious Diseases recently published its support for dengue vaccination. National medical societies in Indonesia, Brazil and Mexico recently also recommended vaccination with Dengvaxia, a company statement said.

In the clinical study population nine years old and older, the dengue vaccine has been documented to prevent two-thirds of dengue cases due to all four serotypes of dengue.

The dengue vaccine also prevented eight of 10 hospitalisations due to dengue and 93 per cent of serious dengue cases like the deadly hemorrhagic form of the disease, over the 25-month study follow-up period of the large-scale efficacy studies conducted in 10 endemic countries in Latin America and Asia.

--IANS

gb/vt

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 04 2016 | 4:08 PM IST

Next Story